Instytut Psychiatrii i Neurologii – ośrodek naukowo-badawczy i kliniczny z siedzibą w Warszawie, zajmujący się prowadzeniem badań własnych w zakresie psychiatrii i neurologii oraz koordynowaniem ich w skali kraju, ...

During the past decade, Instytut Psychiatrii i Neurologii conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 14 clinical trials were completed, i.e. on average, 56% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 12 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instytut Psychiatrii i Neurologii" #1 sponsor was "Hoffmann-La Roche" with 5 trials, followed by "Wave Life Sciences Ltd." with 5 trials sponsored, "Celgene" with 4 trials sponsored, "Idorsia Pharmaceuticals Ltd." with 2 trials sponsored and "Alexion" with 2 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instytut Psychiatrii i Neurologii" #1 collaborator was "National Center for Research and Development, Poland" with 2 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Instytut Psychiatrii i Neurologii" are "Huntington Disease" (4 trials), "Multiple Sclerosis" (4 trials), "Huntington's Disease" (3 trials), "Insomnia Disorder" (2 trials) and "Relapsing Multiple Sclerosis" (2 trials). Many other conditions were trialed in "Instytut Psychiatrii i Neurologii" in a lesser frequency.

Most popular intervention types in "Instytut Psychiatrii i Neurologii" are "Drug" (26 trials), "Other" (3 trials), "Behavioral" (1 trials), "Biological" (1 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "Interferon beta-1a" (3 trials), "Ozanimod" (3 trials), "Daridorexant 25 mg" (2 trials) and "Daridorexant 50 mg" (2 trials). Other intervention names were less common.

The vast majority of trials in "Instytut Psychiatrii i Neurologii" are 31 trials for "All" genders.

Currently, there are NaN active trials in "Instytut Psychiatrii i Neurologii". undefined are not yet recruiting, 5 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Instytut Psychiatrii i Neurologii, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Instytut Psychiatrii i Neurologii, 6 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".

Instytut Psychiatrii i Neurologii has several departments that took part in Clinical trials: "Instytut Psychiatrii i Neurologii II Klinika Neurologiczna" - 11 trials